Glaukos, which sells micro-scale surgical devices for treating glaucoma, announced terms for its IPO on Monday. The Laguna Hills, CA-based company plans to raise $75 million by offering 5.4 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Glaukos would command a fully diluted market value of $474 million.
Glaukos, which was founded in 1998 and booked $52 million in sales for the 12 months ended March 31, 2015, plans to list on the NYSE under the symbol GKOS. Glaukos initially filed confidentially on 7/23/2014. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs are the joint bookrunners on the deal. It is expected to price during the week of June 22, 2015.
The article Glaucoma device maker Glaukos sets terms for $75 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
